Astellas sees potential in bi-specific macrophage engagers

28 December 2023
astellas_big

Privately-held Chinese firm Elpiscience Biopharma has inked a deal with Japan’s Astellas Pharma (TYO: 4503) related to two novel bi-specific macrophage engagers (BiME).

A new technology, BiMEs can be designed with different surface properties, thereby allowing macrophages to attack a range of different tumor cells.

The deal covers development of the candidate ES019, and another undisclosed program.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology